Politics & Law
DEA Comments Gaffe
The DEA (Drug Enforcement Agency) has ordained its decree: Another year, another decrease in the production quota for prescription opioids.
Read more
Mental Health Courts Struggle to Fulfill Mission
Advocates, attorneys, clinicians, and researchers say mental health courts struggle to live up to their promise.
Read more
Physicians: Write Legal Briefs
In recent years, there has been an increasing need for physicians to participate in complex healthcare legal cases by writing...
Read more
Opioid Settlements: “Cash Cow”
“It’s heartbreaking to see what the government is doing with this money. Putting it in places they really don’t need...
Read more
Black Swans of Health Policy
Don’t worry about the healthcare laws. Worry about the changing legal interpretations of existing healthcare laws.
Read more
Gun Education is Harm Reduction
As a former marine and emergency medicine physician, I bring a unique perspective on gun control and ownership.
Read more
We May Soon Have a Nitazene Crisis
A drug testing service reported that, since September, nitazenes were found in 20 samples of black market benzodiazepines.
Read more
Addiction Isn’t Just Genetic
The impact of behavioral factors on addiction is a complex and multifaceted topic that continues to be researched and explored.
Read more
Abortion: Harbinger of Healthcare
We saw two major cases on abortion this week. Unfortunately, this feels like a harbinger of things to come.
Read more
SCOTUS Likely to Favor Sackler’s
As the nation grapples with the overdose epidemic, the legal battle surrounding Purdue Pharma's bankruptcy immunity has taken center stage.
Read more
Conflating the Migrant and Overdose Crises
While the rhetoric surrounding closing the border may seem appealing, it is essential to critically analyze the potential consequences.
Read more
Serious About Expanding Access to Methadone
The Senate Committee on Health, Education, Labor, and Pensions is scheduled to consider the Modernizing Opioid Treatment Access Act (MOTAA).
Read more
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more